Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Inhibikase Therapeutics (IKT) over the last 5 years, with Q3 2025 value amounting to $90.1 million.

  • Inhibikase Therapeutics' Shares Outstanding (Diluted Average) rose 91379.41% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 91379.41%. This contributed to the annual value of $23.7 million for FY2024, which is 29335.42% up from last year.
  • Per Inhibikase Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $90.1 million for Q3 2025, which was up 91379.41% from $90.0 million recorded in Q2 2025.
  • Inhibikase Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $90.1 million for Q3 2025, and its period low was $4.2 million during Q4 2022.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $24.1 million, with a median of $8.2 million in 2024.
  • In the last 5 years, Inhibikase Therapeutics' Shares Outstanding (Diluted Average) plummeted by 8319.93% in 2022 and then soared by 131210.3% in 2025.
  • Quarter analysis of 5 years shows Inhibikase Therapeutics' Shares Outstanding (Diluted Average) stood at $18.2 million in 2021, then crashed by 76.81% to $4.2 million in 2022, then soared by 42.74% to $6.0 million in 2023, then skyrocketed by 293.35% to $23.7 million in 2024, then skyrocketed by 279.77% to $90.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $90.1 million in Q3 2025, compared to $90.0 million in Q2 2025 and $89.5 million in Q1 2025.